Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead

RAD51 is integral in homologous recombination DNA damage repair and has garnered much interest as both a biomarker and potential therapeutic target in oncology. Multiple in vitro and in vivo studies have demonstrated its role as a predictive marker, particularly in the context of platinum-based ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsang, Erica S, Munster, Pamela N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758980/
https://www.ncbi.nlm.nih.gov/pubmed/36536949
http://dx.doi.org/10.2147/OTT.S322297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758980/
https://www.ncbi.nlm.nih.gov/pubmed/36536949
http://dx.doi.org/10.2147/OTT.S322297

Ejemplares similares